NCI Cancer Moonshot Scholars program (R01)

RFA-CA-22-050

93rd Meeting of the NCI Council of Research Advocates (NCRA)

LeeAnn Bailey, MD, PhD September 18, 2024





EQUITY & INCLUSION

Program Overview

NCI Equity & Inclusion Program (EIP)



NCI is committed to address inequities within the biomedical community. The EIP was launched to:

- Build a more equitable and inclusive NCI community.
- Increase the diversity of the cancer research workforce.
- Address cancer disparities and advance health equity.

NCI supports the National Institutes of Health's UNITE initiative.

EIP Program Structure

EQUITY COUNCIL

Council Chair Kimryn Rathmell **Co-Chair**Paulette Gray

Anne Lubenow Andrea Apolo Dinah Singer Donna Siegle Shannon Bell Nelvis Castro Ji Luo Sanya Springfield Gary Ellison

Working Group 1

Enhancing
Research to
Address Cancer
Health Disparities

Co-Chairs: Jim Doroshow Tiffany Wallace

Working Group 2

Ensuring Diversity of Thought and Background in the Cancer Research Workforce

Co-Chairs:

LeeAnn Bailey Shannon Hughes

Working Group 3

Promoting an
Equitable and
Inclusive
Community at NCI

Co-Chairs:

Shannon Bell Paige Green Satish Gopal

Working Group 4

Systematic Tracking and Evaluation of Equity Activities

Co-Chairs:

Michelle Berny-Lang Christine Burgess

Working Group 5

Communications and Outreach for Equity Activities

Co-Chairs:

Peter Garrett Angela Jones Anita Linde



Background

NCI designed the Cancer Moonshot Scholars program to advance cancer research, while also diversifying the pool of researchers and the approaches to cancer research that NCI funds.



- A diverse biomedical research workforce is essential for solving complex health challenges, including cancer.
 - Diverse cultural perspectives are essential to reach diverse communities.
 - Diverse approaches and ways of thinking support the advancement of research.

 Despite contributions of numerous diversity-focused programs at NIH and beyond, some groups remain underrepresented in the biomedical and behavioral sciences.

Goals for new phase of the Cancer Moonshot

The White House's Cancer Cabinet identified a priority of the Cancer Moonshot 2.0 is to support diversity:

- Inspire and support the next generation of diverse, innovative cancer researchers
- Increase diversity of cancer research and care workforce to better resemble the communities we serve



First Cancer Cabinet Meeting, at the White House on March 16, 2022.



BRIEFING ROOM


Fact Sheet: White House Announces Initial Steps for Reignited Cancer Moonshot

MARCH 17, 2022

PRESS RELEASES

Purpose and Goals of CMSp

This RFA aligns with the priorities identified by White House's Cancer Cabinet to inspire and support the next generation of diverse cancer researchers:



Goals

- Promote scientific advances in cancer research by increasing diversity of thought and perspective in NCIs funded portfolio
- Support Early-Stage Investigators (ESI)
- To increase the number of funded R01 investigators from URGs across the cancer research continuum



Discovery science is an essential input for the health-centric goals and a vehicle for the empowering goals in many cases. All goals together contribute to improved health outcomes-for all.

Research Scope for RFA-CA-22-050

Proposed research must align with the NCI's mission

- Encompasses all areas of cancer research including cancer biology, prevention, diagnosis, treatment, and control.
- Encompasses all research disciplines including basic, translational, clinical, and/or populationbased studies.
- Broad scope is similar to the Parent R01, with the research proposal intended to be investigatorinitiated





https://www.cancer.gov/about-nci/overview

The CMSp First Two Cohorts (2023, 2024)

2023 Cohort

- 1st Submission Date: November 8, 2022
- 11 applications awarded, July 2023



As Part of Unity Agenda, Biden Cancer Moonshot Announces Inaugural Cohort of Cancer Moonshot Scholars and Awards \$5.4 Million to Advance Cancer Research and Innovation

THE WHITE HOUSE

2024 & 2025 Cohorts



Research Projects

Cancer sites: Lung, Blood, Breast, Brain, Rectal, Hepatocellular, Prostate, Cervical, Pancreatic

Approaches: Screening, Intervention, Basic sciences, Treatment, Diagnostics, Prevention, Implementation Science

Acknowledgements and Thanks

CMSp RFA Scientific Program Contacts:

- Brandy Heckman-Stoddard (DCP)
- Amy Kennedy (DCCPS)
- Richard Moser (DCCPS)
- Leah Hubbard (DCTD)
- Eric Johnson (DCB)
- Sudha Sivaram (OD/CGH)
- Tiffany Wallace (CRCHD)

NCI Leadership:

- Dinah Singer
- Sanya A. Springfield



CMSp Team:

Tiffany Wallace (Co-Lead) Neeraja Sathyamoorthy Brian Davis

Collaborators:

Shannon Hughes Christine Burgess

